Modality
Multispecific
MOA
GLP-1/GIP
Target
JAK2
Pathway
RAS/MAPK
PompeCLLMeso
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
~Mar 2022
→ ~Jun 2023
Phase 2
Sep 2023
→ Nov 2031
Phase 2Current
NCT08150402
126 pts·Pompe
2023-09→2031-11·Not yet recruiting
NCT06479810
2,000 pts·CLL
2025-08→2029-09·Recruiting
2,126 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-08-044mo awayFast Track· Pompe
2029-09-123.5y awayPh3 Readout· CLL
2031-11-065.6y awayPh3 Readout· Pompe
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Not yet…
P2/3
Recruit…
Catalysts
Fast Track
2026-08-04 · 4mo away
Pompe
Ph3 Readout
2029-09-12 · 3.5y away
CLL
Ph3 Readout
2031-11-06 · 5.6y away
Pompe
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08150402 | Phase 2/3 | Pompe | Not yet recr... | 126 | NT-proBNP |
| NCT06479810 | Phase 2/3 | CLL | Recruiting | 2000 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 |